3.32  0.01 (0.3%)		12-08 16:00
Open: 3.24 High: 3.4 Volume: 13,091		Pre. Close: 3.31 Low: 3.015 Market Cap: 157(M)

Short term
Mid term
Targets	6-month :	4.69	1-year :	5.41
Resists	First :	4.01	Second :	4.63
Pivot price	3.69
Supports	First :	3.01	Second :	2.5
MAs	MA(5) :	3.35	MA(20) :	3.83
	MA(100) :	4.9	MA(250) :	8.17
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	12.4	D(3) :	8.8
RSI	RSI(14): 35.5
52-week	High :	10.93	Low :	2.63

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALUR ] has closed above bottom band by 17.0%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.41 - 3.43	3.43 - 3.44
Low:	2.96 - 2.99	2.99 - 3.01
Close:	3.28 - 3.32	3.32 - 3.35

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Fri, 24 Nov 2023
Allurion Technologies Inc.'s (NYSE:ALUR) last week's 14% decline must have disappointed retail investors who have a significant stake - Simply Wall St

Mon, 13 Nov 2023
Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update - Business Wire

Mon, 06 Nov 2023
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023 - Business Wire

Wed, 11 Oct 2023
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon - Business Wire

Wed, 04 Oct 2023
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023 - Business Wire

Tue, 19 Sep 2023
Allurion Technologies Files for Potential Secondary Offering -September 19, 2023 at 03:45 am EDT - Marketscreener.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NYSE
Sector: Healthcare
Industry: Medical Devices
Shares Out	47 (M)
Shares Float	31 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	539 (K)
Shares Short P.Month	557 (K)

EPS	-1.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.12
Profit Margin	-114.6 %
Operating Margin	-109.7 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	13.3 %
Gross Profit (p.s.)	0
Sales Per Share	1.35
EBITDA (p.s.)	-1.2
Qtrly Earnings Growth	0 %
Operating Cash Flow	-59 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-2.07
PEG Ratio	0
Price to Book value	-3
Price to Sales	2.44
Price to Cash Flow	-2.68

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.